You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School
Dow
McKesson
Colorcon

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 9,034,391

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,034,391
Title:Compositions with enhanced bioavailability and fast acting inhibitor or gastric acid secretion
Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion. The present invention also relates to the use of one or more water soluble zinc salts, administered in combination with a therapeutic compound or agent (second therapeutic agent) which may be delivered orally with enhanced bioavailability (compared to compounds which are administered in the absence of water soluble zinc salts) or other favorable benefits. In addition, therapeutic agents which exhibit sensitivity to low pH may be advantageously orally administered in combination with an effective amount of at least one water soluble zinc salt. Compositions according to the present invention exhibit greater bioavailability of the active agent when formulated in combination with a water soluble zinc salt in oral dosage form than when administered with the water soluble zinc salt.
Inventor(s): Geibel; John P. (Branford, CT), Kirchhoff; Philipp (Attendorn, DE)
Assignee: YALE UNIVERSITY (New Haven, CT)
Application Number:12/452,637
Patent Claims:see list of patent claims

Details for Patent 9,034,391

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial YALE UNIVERSITY (New Haven, CT) 2026-01-27 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial YALE UNIVERSITY (New Haven, CT) 2026-01-27 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial YALE UNIVERSITY (New Haven, CT) 2026-01-27 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial YALE UNIVERSITY (New Haven, CT) 2026-01-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Dow
Medtronic
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.